Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering

Rapid Micro Biosystems, Inc. has announced a significant fundraising initiative, pricing an underwritten offering aimed at raising approximately $32 million. The offering consists of 3,581,000 shares of Class A common stock, along with accompanying Series A and Series B warrants. The combined offering price is set at $1.955 per share, with the transaction expected to close on May 20, 2026. This move is backed by existing investor Bain Capital Life Sciences and healthcare-focused institutional investor Armistice Capital LLC.

The funds raised from this offering are expected to provide Rapid Micro Biosystems with gross proceeds of approximately $9.8 million, with an additional potential of $21.7 million from the exercise of the associated warrants. The Series A warrants will have an exercise price of $1.955 per share and will be exercisable six months from the date of issuance, while the Series B warrants will be priced at $2.34 per share, exercisable six months after issuance and expiring five years later. This structured approach allows the company to secure immediate capital while also providing investors with the opportunity to increase their stake in the company through warrant exercises.

Founded to address the inefficiencies in microbial quality control testing, Rapid Micro Biosystems has developed the Growth Direct system, which automates critical processes in the manufacturing of healthcare products, including biologics, vaccines, and sterile injectables. The company positions itself as a leader in life sciences technology, focusing on the modernization of quality control workflows that have traditionally relied on manual processes. This fundraising effort is likely to enhance its capabilities and expand its market presence.

The life sciences sector is currently experiencing robust growth, driven by increasing demand for innovative healthcare solutions and advancements in technology. Investments in automation and efficiency are paramount as companies strive to meet regulatory standards while improving production timelines. Rapid Micro Biosystems' offering is strategically timed to capitalize on these sector dynamics, allowing it to strengthen its operational infrastructure and potentially accelerate the development of its product offerings.

In summary, the successful completion of this fundraising initiative could have broader implications for the life sciences market, particularly in the automation space. As companies like Rapid Micro Biosystems secure necessary capital, they may drive further innovation and efficiency within the sector, ultimately benefiting healthcare providers and patients alike. The ongoing support from established investors like Bain Capital Life Sciences and Armistice Capital LLC underscores the confidence in the company's growth trajectory and its pivotal role in transforming the life sciences landscape.